⚠ Evidence warning: Clinical trials or other evidence do not support the claim that whole-brain radiation therapy added to chemotherapy improves central nervous system penetration and reduces the risk of bleeding in the brain from treated lesions. This page keeps it as a report of what people, websites or other media say.

Gestational Trophoblastic Disease

Table of Contents

  1. Overview and Classification
  2. Complete Hydatidiform Mole
  3. Partial Hydatidiform Mole
  4. Gestational Choriocarcinoma
  5. Rare GTN Types
  6. Clinical Presentation
  7. Diagnosis
  8. FIGO Staging and WHO Scoring
  9. Treatment
  10. Surveillance After Molar Pregnancy
  11. Key Research Papers
  12. Featured Videos

Overview and Classification

Gestational Trophoblastic Disease (GTD) is a spectrum of neoplasms arising from abnormal trophoblast proliferation after conception. The trophoblast normally invades the maternal decidua and remodels spiral arteries during normal pregnancy; in GTD, this process becomes pathological, resulting in a group of conditions ranging from benign or pre-malignant molar pregnancies to highly aggressive malignant tumors collectively called Gestational Trophoblastic Neoplasia (GTN).

A defining feature of virtually all GTD types is production of beta-human chorionic gonadotropin (beta-hCG), the same hormone detected in standard pregnancy tests. This makes hCG an almost perfect tumor marker — it can be used to monitor treatment response, detect relapse, and guide decisions about when surveillance can be safely concluded.

Classification

Benign / Pre-malignant:

Malignant (Gestational Trophoblastic Neoplasia, GTN):

Because all GTD types secrete beta-hCG, serial quantitative hCG measurement is the cornerstone of both initial diagnosis and long-term surveillance for every woman treated for GTD.

In 2025, four international groups (the European Organisation for the Treatment of Trophoblastic Diseases, the European Society of Gynaecological Oncology, the Gynecologic Cancer InterGroup and the International Society for the Study of Trophoblastic Diseases) published what they describe as the first global consensus guidelines for GTD. Fifty-three GTD specialists from 31 countries agreed nine definitions, the minimum requirements for a GTD center, and 18 flow diagrams covering diagnosis, treatment and follow-up of every form of first-time or returning GTD. The International Federation of Gynecology and Obstetrics (FIGO) also issued a 2025 update of its own GTD report.

Back to Table of Contents

Complete Hydatidiform Mole

Genetics and Pathology

Complete hydatidiform moles have entirely paternal chromosomal origin — a condition called androgenetic diploidy. The mechanism involves an empty oocyte (enucleated, with no maternal chromosomes) that is fertilized either by a single sperm that then duplicates its own chromosomes (resulting in 46,XX; accounts for roughly 90% of complete moles) or by two sperm simultaneously (resulting in 46,XX or 46,XY). In either case, there is no maternal nuclear DNA contribution.

The result is diffuse hydropic swelling of all chorionic villi, producing the classic grape-like cluster of vesicles. There is no fetal tissue and no fetal red blood cells — distinguishing CHM from partial moles and from hydropic abortion.

Pathophysiology

The unchecked trophoblastic proliferation occurs without fetal development and drives markedly elevated hCG levels — often exceeding 100,000 mIU/mL. Very high hCG has several downstream effects:

Ultrasound Appearance

The classic ultrasound finding is the snowstorm appearance — a heterogeneous, echogenic mass filling the uterine cavity with multiple small anechoic cystic spaces corresponding to the hydropic villi. There is no fetal pole or fetal heartbeat. Bilateral theca lutein cysts may be visible as multilocular adnexal masses.

Risk of Malignant Transformation

Approximately 15–20% of complete moles progress to post-molar GTN. Risk factors for progression include uterine size significantly larger than gestational dates, theca lutein cysts greater than 6 cm, very high hCG exceeding 100,000 mIU/mL, and age over 40. These factors identify women who need especially close post-evacuation hCG surveillance.

Back to Table of Contents

Partial Hydatidiform Mole

Genetics and Pathology

Partial hydatidiform moles are typically triploid — carrying three sets of chromosomes (69,XXX or 69,XXY) — resulting from dispermy: two sperm fertilizing a single normal egg. Unlike complete moles, partial moles usually contain some fetal tissue, though fetal development is severely abnormal and non-viable. The hydropic change is partial — some villi are swollen and edematous while others remain histologically normal — creating a mixed picture on both gross examination and microscopy.

Clinical Distinction from CHM

Partial moles differ from complete moles in several clinically important ways:

Risk of Malignant Transformation

Only 0.5–5% of partial moles progress to GTN, according to FIGO's 2025 update, making the malignant risk substantially lower than for complete moles. Partial moles are still followed with hCG after evacuation, because the small percentage that do transform are fully treatable if detected early; the length of follow-up differs (see Surveillance).

Flow cytometry (ploidy analysis performed on the evacuated tissue) is a useful ancillary test that helps pathologists distinguish CHM (diploid, androgenetic) from PHM (triploid) from hydropic abortion (diploid, biparental origin), particularly when histologic features overlap.

Back to Table of Contents

Gestational Choriocarcinoma

Gestational choriocarcinoma is the most aggressive form of GTN. Unlike hydatidiform moles — which are always associated with the current molar pregnancy — choriocarcinoma can follow any type of pregnancy, with different antecedent events accounting for varying proportions of cases:

Pathology

Unlike moles, choriocarcinoma contains no chorionic villi — it consists entirely of sheets of malignant trophoblastic cells (cytotrophoblast and syncytiotrophoblast) with extensive necrosis and hemorrhage. hCG is markedly elevated, reflecting the high trophoblastic cell mass.

Metastatic Pattern

Choriocarcinoma spreads early via the bloodstream. The most common site of metastasis is the lungs (producing the characteristic "cannonball" metastases — multiple discrete rounded lung nodules on chest X-ray). Other common metastatic sites include the vagina, liver, and brain. Neurological symptoms or coughing up blood (hemoptysis) in a woman of reproductive age — especially after a recent pregnancy — are a recognised reason for an immediate quantitative hCG measurement.

Clinical pearl: In a woman of reproductive age with lung metastases of uncertain origin, a pregnancy test is a standard part of the workup. A positive result, combined with lung masses and elevated hCG, is virtually diagnostic of choriocarcinoma until proven otherwise.

Chemosensitivity

Despite its aggressive biology and frequent metastatic presentation, gestational choriocarcinoma is among the most chemosensitive solid tumors known. FIGO's 2025 update reports overall survival above 96% for high-risk GTN, using regimens built around methotrexate and actinomycin-D for low-risk disease and EMA-CO combination chemotherapy for high-risk or refractory cases.

Back to Table of Contents

Rare GTN Types

Placental-Site Trophoblastic Tumor (PSTT)

PSTT arises from intermediate trophoblast — the trophoblastic cell type responsible for implantation site invasion — rather than from villous trophoblast. This origin has important practical consequences. Intermediate trophoblast cells secrete human placental lactogen (hPL) in preference to hCG, meaning hCG levels in PSTT are characteristically low or only mildly elevated despite significant tumor burden. This makes hCG a less reliable marker for monitoring than it is in other GTN types.

PSTT typically presents weeks to years after a seemingly normal term delivery, with abnormal uterine bleeding. It is relatively chemoresistant, in sharp contrast to choriocarcinoma. Surgery (hysterectomy) is the primary treatment, and adjuvant chemotherapy is reserved for metastatic or recurrent disease. Because of this surgical requirement, fertility preservation is generally not possible for PSTT.

Epithelioid Trophoblastic Tumor (ETT)

ETT is the rarest GTN subtype, also arising from intermediate trophoblast. Histologically, ETT can resemble squamous cell carcinoma or poorly differentiated carcinoma, making diagnosis challenging; immunohistochemistry for trophoblastic markers is essential. Like PSTT, ETT produces low hCG levels and is relatively chemoresistant. Surgical resection is the primary treatment approach.

Both PSTT and ETT are important to distinguish from choriocarcinoma because their management is fundamentally different — predominantly surgical rather than chemotherapy-based — and because standard EMA-CO chemotherapy that cures choriocarcinoma is far less effective against these intermediate trophoblast tumors.

Back to Table of Contents

Clinical Presentation

Molar Pregnancy (CHM and PHM)

The most common presenting symptom is vaginal bleeding, occurring in approximately 97% of women with hydatidiform mole. The bleeding is typically painless and may range from spotting to heavy hemorrhage. Because the clinical picture overlaps with early pregnancy complications (threatened abortion, missed abortion), GTD is often first suspected during ultrasound evaluation of first-trimester bleeding.

Other common presentations include:

Gestational Choriocarcinoma

Choriocarcinoma may present in a delayed fashion — weeks, months, or even years after the antecedent pregnancy. Clinical patterns include:

The wide interval between antecedent pregnancy and choriocarcinoma presentation means that a high index of suspicion is required — the diagnosis is considered in any woman of reproductive age with unexplained lung nodules, neurological symptoms, or persistently elevated hCG.

Back to Table of Contents

Diagnosis

Diagnosis of GTD combines clinical assessment, ultrasound findings, quantitative hCG measurement, uterine evacuation, and histopathologic examination. No single test is sufficient; all components contribute to accurate diagnosis and staging.

Ultrasound

Pelvic ultrasound is usually the first investigation to suggest molar pregnancy. Classic findings in CHM include the snowstorm pattern — a hyperechoic intrauterine mass with multiple small cystic spaces — absence of a fetal pole or fetal cardiac activity, and bilateral theca lutein cysts. PHM may show a gestational sac with a ratio of transverse to anteroposterior dimensions greater than 1.5, and focal cystic changes within the placental tissue, but these findings are subtle and PHM is frequently missed on ultrasound.

Quantitative Beta-hCG

Quantitative serum beta-hCG is essential for both diagnosis and ongoing surveillance. In CHM, hCG is often markedly elevated — frequently exceeding 100,000 mIU/mL. PHM typically shows lower elevations. Very high hCG, or an hCG level out of step with gestational age, raises suspicion of molar pregnancy. In GTN diagnosed after molar evacuation, the hCG pattern (plateau, rise, or failure to normalize) defines post-molar GTN without requiring histologic confirmation.

Uterine Evacuation

Suction curettage (vacuum aspiration) serves both as treatment and as the means of obtaining tissue for histopathology. It is the preferred method of uterine evacuation for both CHM and PHM. FIGO's 2025 update states that an intravenous oxytocin infusion may be started at the beginning of the procedure and continued for several hours afterwards, to help the uterus contract and reduce blood loss. Medical induction of labor is avoided in molar pregnancy. Anti-D immunoglobulin is given to Rh-negative women after evacuation.

Histopathology

Histopathologic examination of evacuated tissue is mandatory after every molar evacuation. The pathologist assesses the degree of trophoblastic hyperplasia, the pattern of villous swelling, the presence or absence of fetal tissue, and immunohistochemical markers. Flow cytometry (DNA ploidy analysis) on evacuated tissue helps distinguish CHM (diploid, androgenetic) from PHM (triploid) from hydropic abortion (diploid, biparental) when histologic features are ambiguous.

Pre-treatment Workup for GTN

Once GTN is suspected or diagnosed, a full pre-treatment evaluation includes chest X-ray (to detect pulmonary metastases — "cannonball" lesions in choriocarcinoma), computed tomography (CT) of chest/abdomen/pelvis, and magnetic resonance imaging (MRI) brain if cerebral metastases are clinically suspected. These staging investigations determine FIGO stage and WHO risk score, which together guide choice of chemotherapy regimen.

Back to Table of Contents

FIGO Staging and WHO Scoring

FIGO Anatomic Staging

GTN is staged using the FIGO system based on extent of disease spread:

WHO Prognostic Scoring System

FIGO staging alone does not predict chemotherapy response. The WHO prognostic score (modified and adopted by FIGO) assigns numerical points to eight risk factors, and the total score determines whether single-agent or multi-agent chemotherapy is used:

Risk Stratification and Treatment Assignment

Low-risk GTN (WHO score ≤ 6): Single-agent chemotherapy. The two standard options are:

About 30% of low-risk patients develop resistance to the first single drug (hCG stops falling or rises). Switching from methotrexate to actinomycin-D brings a response in 76–87%, especially when the hCG level is relatively low, and other patients move on to combination chemotherapy. With this step-by-step approach, FIGO reports that overall survival in low-risk GTN approaches 100%.

High-risk GTN (WHO score ≥ 7): Multi-agent combination chemotherapy. The standard regimen is EMA-CO:

About 20% of patients do not respond fully to EMA-CO, but most are cured with further treatment, so FIGO's 2025 update reports overall survival for high-risk GTN now above 96% (its summary gives about 90% for high-risk disease treated with combination chemotherapy) — a remarkable outcome for what would otherwise be a rapidly fatal malignancy.

Brain Metastases

When cerebral metastases are present (FIGO Stage IV), whole-brain radiation therapy or intrathecal methotrexate is added to systemic EMA-CO to improve central nervous system (CNS) penetration and reduce the risk of intracranial hemorrhage from treated lesions.

When cerebral metastases are present (FIGO Stage IV), FIGO's 2025 update describes raising the methotrexate infusion to 1 g/m² so that the drug crosses the blood–brain barrier into the central nervous system (CNS), with intrathecal methotrexate 12.5 mg (injected into the spinal fluid) used in some centers. Some centers also give whole-brain radiotherapy or targeted (stereotactic) radiation, but FIGO states there is no evidence that whole-brain radiotherapy improves cure rates and that it adds long-term toxicity; the 2025 international guidelines do not recommend it.

Back to Table of Contents

Treatment

Molar Pregnancy: Uterine Evacuation

The definitive treatment for both CHM and PHM is suction curettage (vacuum aspiration), performed under ultrasound guidance to minimize the risk of uterine perforation. Key procedural considerations include:

Contraception During Surveillance

Combined oral contraceptive pills (COCPs) are the preferred contraceptive method during hCG surveillance after molar evacuation. A new pregnancy during surveillance would make hCG interpretation impossible, potentially masking residual or recurrent trophoblastic disease. There is no evidence that COCPs increase the risk of post-molar GTN, and they are safe to start immediately after evacuation.

Treatment of GTN

Chemotherapy selection follows the WHO risk score as described in the FIGO Staging section. Important additional points:

Fertility and Pregnancy After GTD

For women treated with chemotherapy for GTN, fertility is preserved and subsequent pregnancies carry no increased risk of congenital abnormalities, miscarriage, or obstetric complications compared with the general population. This is one of the most reassuring and important facts to communicate to young women facing a GTD diagnosis.

Back to Table of Contents

Surveillance After Molar Pregnancy

hCG Surveillance Protocol

After uterine evacuation for molar pregnancy, serial quantitative serum beta-hCG measurements are the cornerstone of post-treatment surveillance. The standard protocol is:

FIGO bases the shorter schedule on the finding that GTN rarely follows a mole once hCG has returned to normal on its own. After chemotherapy for GTN, FIGO describes monthly hCG for at least 12 months, with reliable contraception throughout that period.

Most complete moles achieve hCG normalization within 9–14 weeks of evacuation. Partial moles typically normalize faster. Persistent elevation beyond these timelines, or any of the diagnostic criteria listed below, triggers evaluation and treatment for post-molar GTN.

Diagnosis of Post-Molar GTN

FIGO's criteria (modified in 2021 and restated in its 2025 update) diagnose post-molar GTN when any one of the following is met:

These criteria are deliberately sensitive — they are designed to catch early GTN development before it becomes metastatic, when cure with minimal chemotherapy is virtually guaranteed.

Pregnancy After Surveillance

Women who complete hCG surveillance without evidence of GTN can attempt pregnancy immediately afterward. There is no evidence that waiting longer than the surveillance period improves outcomes, and delaying pregnancy beyond what is medically necessary may cause unnecessary distress to women who are eager to conceive. Normal fertility, normal obstetric outcomes, and normal fetal development have been consistently documented in large series of women after both molar pregnancy and GTN treatment.

Back to Table of Contents

Key Research Papers

  1. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-729. — PubMed PMID: 20673583
  2. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Update on the diagnosis and management of gestational trophoblastic disease. FIGO Cancer Report. Int J Gynaecol Obstet. 2018;143 Suppl 2:79-85. — PubMed PMID: 30306586
  3. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112(3):654-662. — PubMed PMID: 18851873
  4. Lybol C, Thomas CM, Bulten J, van Dijck JA, Sweep FC, Massuger LF. Increase in the incidence of gestational trophoblastic disease in The Netherlands. Gynecol Oncol. 2011;121(2):334-338. — PubMed PMID: 21247618
  5. Sebire NJ, Seckl MJ. Gestational trophoblastic disease: current management of hydatidiform mole. BMJ. 2008;337:a1193. — PubMed PMID: 18708429
  6. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease. Am J Obstet Gynecol. 2010. — Search PubMed
  7. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011. — PubMed PMID: 20739008
  8. Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia: a progress report. J Reprod Med. 2002. — PubMed PMID: 12092012
  9. Eysbouts YK, Bulten J, Ottevanger PB, Thomas CM, Ten Kate-Booij MJ, van Herwaarden AE, Siebers AG, Sweep FC, Massuger LF. Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol. 2016;140(1):70-75. — PubMed PMID: 26586414
  10. Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012. — Search PubMed
  11. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Braga A, Garrett A. Diagnosis and management of gestational trophoblastic disease: 2025 update. Int J Gynaecol Obstet. 2025;171 Suppl 1:78-86. — PubMed PMID: 40631439
  12. Lok C, van Trommel N, Braicu EI, Planchamp F, Berkowitz R, Seckl M; EOTTD-ESGO-GCIG-ISSTD Guideline Committee. Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD). J Clin Oncol. 2025;43(18):2119-2128. — PubMed PMID: 40359461
  13. Ghorani E, Hayes EJ, Maher GJ, Lai SL, Bagislar Bremang S, Kaur B, et al. An International Study of Pembrolizumab for Drug-Resistant Gestational Trophoblastic Neoplasia. NEJM Evid. 2026;5(11):EVIDoa2600044. — PubMed PMID: 42937425

PubMed topic search: Gestational Trophoblastic Disease on PubMed

Back to Table of Contents

Connections